[{"id":"460f1e61-72a2-48bb-a37c-e804016f6240","acronym":"NCI-2021-06095","url":"https://clinicaltrials.gov/study/NCT05010122","created_at":"2021-08-18T15:53:42.501Z","updated_at":"2025-02-25T15:12:15.219Z","phase":"Phase 1/2","brief_title":"ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","source_id_and_acronym":"NCT05010122 - NCI-2021-06095","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FLT3","pipe":" | ","alterations":" FLT3-ITD mutation • FLT3 mutation","tags":["FLT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FLT3-ITD mutation • FLT3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Xospata (gilteritinib) • Inqovi (decitabine/cedazuridine)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 07/08/2021","start_date":" 07/08/2021","primary_txt":" Primary completion: 01/30/2026","primary_completion_date":" 01/30/2026","study_txt":" Completion: 01/30/2026","study_completion_date":" 01/30/2026","last_update_posted":"2025-02-13"},{"id":"f2c492b8-d008-47fb-bfe0-8880113c29ed","acronym":"","url":"https://clinicaltrials.gov/study/NCT06113289","created_at":"2023-11-02T15:12:40.366Z","updated_at":"2025-02-25T15:21:01.496Z","phase":"Phase 1/2","brief_title":"A Phase 1B/2A Trial of Combination of ASTX727 with ASTX029 in Acute Myeloid Leukemia","source_id_and_acronym":"NCT06113289","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KRAS • NF1 • PTPN11","pipe":"","alterations":" ","tags":["KRAS • NF1 • PTPN11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inqovi (decitabine/cedazuridine) • beroterkib anhydrous (ASTX029)"],"overall_status":"Suspended","enrollment":" Enrollment 42","initiation":"Initiation: 02/08/2024","start_date":" 02/08/2024","primary_txt":" Primary completion: 05/01/2027","primary_completion_date":" 05/01/2027","study_txt":" Completion: 05/01/2029","study_completion_date":" 05/01/2029","last_update_posted":"2025-02-12"},{"id":"161e5bfa-d426-464a-9703-09d1a3988f05","acronym":"","url":"https://clinicaltrials.gov/study/NCT05600894","created_at":"2022-11-05T15:14:14.733Z","updated_at":"2025-02-25T16:39:25.353Z","phase":"Phase 2","brief_title":"Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm","source_id_and_acronym":"NCT05600894","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Inqovi (decitabine/cedazuridine)"],"overall_status":"Recruiting","enrollment":" Enrollment 132","initiation":"Initiation: 06/27/2023","start_date":" 06/27/2023","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 08/31/2025","study_completion_date":" 08/31/2025","last_update_posted":"2025-02-07"},{"id":"67917d6a-e1b0-409b-853a-7e9fd258dd6d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06802523","created_at":"2025-02-25T16:34:56.075Z","updated_at":"2025-02-25T16:34:56.075Z","phase":"Phase 1","brief_title":"Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia","source_id_and_acronym":"NCT06802523","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD33","pipe":"","alterations":" ","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Inqovi (decitabine/cedazuridine) • Actimab-A (lintuzumab-Ac225)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 04/30/2025","start_date":" 04/30/2025","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-02-07"},{"id":"646a5bb4-c6c5-49c4-b475-0738f83491e5","acronym":"NCI-2021-02246","url":"https://clinicaltrials.gov/study/NCT04817241","created_at":"2021-03-26T15:52:34.807Z","updated_at":"2025-02-25T17:00:59.840Z","phase":"Phase 1/2","brief_title":"Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients","source_id_and_acronym":"NCT04817241 - NCI-2021-02246","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • daunorubicin • Inqovi (decitabine/cedazuridine) • Starasid (cytarabine ocfosfate)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 02/10/2022","start_date":" 02/10/2022","primary_txt":" Primary completion: 10/25/2025","primary_completion_date":" 10/25/2025","study_txt":" Completion: 10/25/2025","study_completion_date":" 10/25/2025","last_update_posted":"2025-02-03"},{"id":"752adfe9-ab45-4296-93ce-d79ee99fa87f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05007873","created_at":"2022-04-24T09:03:10.634Z","updated_at":"2025-02-25T16:26:40.003Z","phase":"Phase 2","brief_title":"ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase","source_id_and_acronym":"NCT05007873","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • Inqovi (decitabine/cedazuridine)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 10/21/2021","start_date":" 10/21/2021","primary_txt":" Primary completion: 10/30/2026","primary_completion_date":" 10/30/2026","study_txt":" Completion: 10/30/2026","study_completion_date":" 10/30/2026","last_update_posted":"2024-08-27"},{"id":"aa92e647-2204-49a9-b0eb-03d672654c30","acronym":"","url":"https://clinicaltrials.gov/study/NCT05037500","created_at":"2021-09-08T14:53:05.286Z","updated_at":"2024-07-02T16:34:27.381Z","phase":"Phase 1","brief_title":"Decitabine/Cedazuridine and Enzalutamide for the Treatment of Metastatic Castrate Resistant Prostate Cancer","source_id_and_acronym":"NCT05037500","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" TP53 • RB1","pipe":"","alterations":" ","tags":["TP53 • RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • Inqovi (decitabine/cedazuridine)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 01/26/2022","start_date":" 01/26/2022","primary_txt":" Primary completion: 01/30/2025","primary_completion_date":" 01/30/2025","study_txt":" Completion: 01/30/2025","study_completion_date":" 01/30/2025","last_update_posted":"2024-06-11"},{"id":"566dbbb6-eabe-4dfb-be9c-7161bcda7964","acronym":"","url":"https://clinicaltrials.gov/study/NCT05960773","created_at":"2023-07-27T18:08:58.951Z","updated_at":"2024-07-02T16:34:37.145Z","phase":"Phase 2","brief_title":"Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma","source_id_and_acronym":"NCT05960773","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BAP1","pipe":" | ","alterations":" BAP1 mutation","tags":["BAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BAP1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inqovi (decitabine/cedazuridine)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 01/31/2024","start_date":" 01/31/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-06-07"},{"id":"068c80f1-b744-42e6-bb47-84aa54ab2e3c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05673200","created_at":"2023-01-06T16:59:14.142Z","updated_at":"2024-07-02T16:34:38.142Z","phase":"Phase 1","brief_title":"Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer","source_id_and_acronym":"NCT05673200","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • PD-L1 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PD-L1 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • paclitaxel • Inqovi (decitabine/cedazuridine) • Pembroria (pembrolizumab biosimilar)"],"overall_status":"Suspended","enrollment":" Enrollment 24","initiation":"Initiation: 09/25/2023","start_date":" 09/25/2023","primary_txt":" Primary completion: 02/23/2027","primary_completion_date":" 02/23/2027","study_txt":" Completion: 02/23/2027","study_completion_date":" 02/23/2027","last_update_posted":"2024-06-05"},{"id":"ab92a282-919a-4023-ac7a-0869d1798034","acronym":"NCI-2021-00893","url":"https://clinicaltrials.gov/study/NCT04774393","created_at":"2021-03-01T14:52:29.975Z","updated_at":"2024-07-02T16:34:59.147Z","phase":"Phase 1/2","brief_title":"Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT04774393 - NCI-2021-00893","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Tibsovo (ivosidenib) • Idhifa (enasidenib) • Inqovi (decitabine/cedazuridine)"],"overall_status":"Recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 05/24/2021","start_date":" 05/24/2021","primary_txt":" Primary completion: 11/29/2024","primary_completion_date":" 11/29/2024","study_txt":" Completion: 11/29/2024","study_completion_date":" 11/29/2024","last_update_posted":"2024-06-04"},{"id":"40f5121b-bb06-4c08-8167-45765aada070","acronym":"KCP-8602-801","url":"https://clinicaltrials.gov/study/NCT02649790","created_at":"2021-01-17T17:34:58.356Z","updated_at":"2024-07-02T16:35:00.978Z","phase":"Phase 1/2","brief_title":"Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications","source_id_and_acronym":"NCT02649790 - KCP-8602-801","lead_sponsor":"Karyopharm Therapeutics Inc","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • dexamethasone • Inqovi (decitabine/cedazuridine) • eltanexor (KPT-8602)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 277","initiation":"Initiation: 01/01/2016","start_date":" 01/01/2016","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-05-24"},{"id":"5f6cead8-271a-4f4a-b549-d12536680be3","acronym":"ETCTN","url":"https://clinicaltrials.gov/study/NCT04340843","created_at":"2023-11-13T22:14:48.481Z","updated_at":"2024-07-02T16:35:03.396Z","phase":"Phase 2","brief_title":"Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma","source_id_and_acronym":"NCT04340843 - ETCTN","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IDH1 • IDH2","pipe":"","alterations":" ","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inqovi (decitabine/cedazuridine) • Beleodaq (belinostat) • guadecitabine (SGI-110)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 09/08/2020","start_date":" 09/08/2020","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-05-16"},{"id":"2291eab5-9fb4-44d5-96f0-82bfe5388eb5","acronym":"GFM-DACORAL-DLI","url":"https://clinicaltrials.gov/study/NCT04857645","created_at":"2021-04-23T21:52:37.777Z","updated_at":"2024-07-02T16:35:11.776Z","phase":"Phase 2","brief_title":"ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients","source_id_and_acronym":"NCT04857645 - GFM-DACORAL-DLI","lead_sponsor":"Groupe Francophone des Myelodysplasies","biomarkers":" TP53 • RUNX1 • ASXL1","pipe":" | ","alterations":" RUNX1 mutation","tags":["TP53 • RUNX1 • ASXL1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RUNX1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inqovi (decitabine/cedazuridine)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 06/22/2021","start_date":" 06/22/2021","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-04-03"},{"id":"be88f98e-0fa1-4b42-a319-2f05034b56b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03922555","created_at":"2021-01-18T19:17:53.739Z","updated_at":"2024-07-02T16:35:12.305Z","phase":"Phase 1","brief_title":"ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas","source_id_and_acronym":"NCT03922555","lead_sponsor":"Massachusetts General Hospital","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inqovi (decitabine/cedazuridine)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 07/12/2019","start_date":" 07/12/2019","primary_txt":" Primary completion: 05/31/2024","primary_completion_date":" 05/31/2024","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2024-03-29"},{"id":"f73911e5-e1de-4e1b-ac56-12e2040f406e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04134884","created_at":"2021-01-18T20:11:32.856Z","updated_at":"2024-07-02T16:35:13.096Z","phase":"Phase 1","brief_title":"Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer","source_id_and_acronym":"NCT04134884","lead_sponsor":"Kathy Miller","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Talzenna (talazoparib) • Inqovi (decitabine/cedazuridine)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 04/01/2020","start_date":" 04/01/2020","primary_txt":" Primary completion: 01/30/2024","primary_completion_date":" 01/30/2024","study_txt":" Completion: 03/14/2024","study_completion_date":" 03/14/2024","last_update_posted":"2024-03-22"},{"id":"8e9016c5-f335-427f-9f26-0ca96ab2e497","acronym":"LANTana","url":"https://clinicaltrials.gov/study/NCT05178693","created_at":"2022-01-05T12:53:41.791Z","updated_at":"2025-02-25T15:54:18.184Z","phase":"Phase 1","brief_title":"Lutathera and ASTX727 in Neuroendocrine Tumours","source_id_and_acronym":"NCT05178693 - LANTana","lead_sponsor":"Imperial College London","biomarkers":" SSTR2","pipe":" | ","alterations":" SSTR2 expression","tags":["SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inqovi (decitabine/cedazuridine) • Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 04/25/2022","start_date":" 04/25/2022","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-03-20"},{"id":"a235b506-8835-43df-8263-a23bea27a842","acronym":"HyPeR","url":"https://clinicaltrials.gov/study/NCT02998567","created_at":"2021-01-18T14:45:00.716Z","updated_at":"2025-02-25T16:05:35.405Z","phase":"Phase 1","brief_title":"Combination Study of Guadecitabine/ASTX727 and Pembrolizumab","source_id_and_acronym":"NCT02998567 - HyPeR","lead_sponsor":"Royal Marsden NHS Foundation Trust","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Inqovi (decitabine/cedazuridine) • guadecitabine (SGI-110)"],"overall_status":"Recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 01/26/2017","start_date":" 01/26/2017","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-03-20"},{"id":"0db68b48-63b4-415c-9bee-7380074c53b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05396859","created_at":"2022-05-31T12:54:45.824Z","updated_at":"2024-07-02T16:35:14.538Z","phase":"Phase 1","brief_title":"Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia","source_id_and_acronym":"NCT05396859","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" TP53 • RUNX1 • MAPK1 • NTRK • MAPK3","pipe":" | ","alterations":" TP53 mutation • NTRK expression","tags":["TP53 • RUNX1 • MAPK1 • NTRK • MAPK3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • NTRK expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rozlytrek (entrectinib) • Inqovi (decitabine/cedazuridine)"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 10/28/2022","start_date":" 10/28/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-03-15"},{"id":"1debacb5-f874-42c5-94ad-4212182706f7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04980404","created_at":"2021-07-28T19:52:31.805Z","updated_at":"2024-07-02T16:35:15.753Z","phase":"Phase 1","brief_title":"Inqovi Maintenance Therapy in Myeloid Neoplasms","source_id_and_acronym":"NCT04980404","lead_sponsor":"Massachusetts General Hospital","biomarkers":" CD33 • HLA-B","pipe":" | ","alterations":" CD33 expression","tags":["CD33 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inqovi (decitabine/cedazuridine)"],"overall_status":"Recruiting","enrollment":" Enrollment 22","initiation":"Initiation: 09/17/2021","start_date":" 09/17/2021","primary_txt":" Primary completion: 08/24/2023","primary_completion_date":" 08/24/2023","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2024-03-08"},{"id":"d92c2904-fae5-49ae-88c5-673b584f9118","acronym":"","url":"https://clinicaltrials.gov/study/NCT04872543","created_at":"2022-03-16T22:55:47.285Z","updated_at":"2024-07-02T16:35:16.749Z","phase":"Phase 2","brief_title":"A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)","source_id_and_acronym":"NCT04872543","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" SUZ12","pipe":" | ","alterations":" EZH2 mutation","tags":["SUZ12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EZH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inqovi (decitabine/cedazuridine)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 04/29/2021","start_date":" 04/29/2021","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-03-01"},{"id":"0f841029-f2ce-4cb1-849c-75709569b46f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03613532","created_at":"2021-03-05T16:52:31.672Z","updated_at":"2024-07-02T16:35:22.047Z","phase":"Phase 1","brief_title":"Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN","source_id_and_acronym":"NCT03613532","lead_sponsor":"Jacqueline Garcia, MD","biomarkers":" KRAS • TP53 • FLT3 • ABL1 • NRAS • BCR • BCL2 • NPM1 • NF1 • RUNX1 • SF3B1 • ASXL1 • KMT2A • PTPN11 • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • DEK • RIT1 • ZRSR2","pipe":" | ","alterations":" TP53 mutation • KRAS mutation • NRAS mutation • RUNX1 mutation • RAS mutation • ASXL1 mutation • CBL mutation • MLL rearrangement • U2AF1 mutation • Chr del(5q) • FLT3 wild-type","tags":["KRAS • TP53 • FLT3 • ABL1 • NRAS • BCR • BCL2 • NPM1 • NF1 • RUNX1 • SF3B1 • ASXL1 • KMT2A • PTPN11 • SRSF2 • BCOR • U2AF1 • STAG2 • MECOM • NUP214 • GATA2 • DEK • RIT1 • ZRSR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • KRAS mutation • NRAS mutation • RUNX1 mutation • RAS mutation • ASXL1 mutation • CBL mutation • MLL rearrangement • U2AF1 mutation • Chr del(5q) • FLT3 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • Inqovi (decitabine/cedazuridine) • fludarabine IV • busulfan"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 10/24/2018","start_date":" 10/24/2018","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-01-26"},{"id":"e2238256-c7a8-4c84-9a16-7bb5eda01432","acronym":"","url":"https://clinicaltrials.gov/study/NCT05089370","created_at":"2021-10-22T12:53:01.331Z","updated_at":"2024-07-02T16:35:45.725Z","phase":"Phase 1/2","brief_title":"Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma","source_id_and_acronym":"NCT05089370","lead_sponsor":"University of Colorado, Denver","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Inqovi (decitabine/cedazuridine)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/20/2022","start_date":" 06/20/2022","primary_txt":" Primary completion: 07/26/2024","primary_completion_date":" 07/26/2024","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2023-06-14"},{"id":"814e661a-25f3-48a9-8987-0deeebc70170","acronym":"PEVOBINE","url":"https://clinicaltrials.gov/study/NCT04985656","created_at":"2021-08-02T14:53:04.830Z","updated_at":"2024-07-02T16:36:23.698Z","phase":"Phase 2","brief_title":"A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes","source_id_and_acronym":"NCT04985656 - PEVOBINE","lead_sponsor":"Takeda","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pevonedistat (MLN4924) • Inqovi (decitabine/cedazuridine)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 01/08/2024","primary_completion_date":" 01/08/2024","study_txt":" Completion: 11/08/2024","study_completion_date":" 11/08/2024","last_update_posted":"2021-09-29"},{"id":"e7d8b286-5707-4030-9fcf-5b8294491103","acronym":"","url":"https://clinicaltrials.gov/study/NCT04013880","created_at":"2021-01-18T19:42:59.261Z","updated_at":"2024-07-02T16:36:43.617Z","phase":"Phase 1/2","brief_title":"ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia","source_id_and_acronym":"NCT04013880","lead_sponsor":"Vanderbilt-Ingram Cancer Center","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 R132","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inqovi (decitabine/cedazuridine) • Rezlidhia (olutasidenib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/27/2019","start_date":" 08/27/2019","primary_txt":" Primary completion: 03/31/2021","primary_completion_date":" 03/31/2021","study_txt":" Completion: 03/31/2022","study_completion_date":" 03/31/2022","last_update_posted":"2020-07-07"}]